Source: Andrew Wynn
Pomerantz LLP Investigates Sarepta Therapeutics Amidst Patient Fatalities
Pomerantz LLP, a leading national law firm, has launched an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on the suspicion of potential securities fraud and unlawful business practices. The probe comes as a response to the two patient fatalities linked to the company’s drug, Elevidys, which is used in the treatment of Duchenne muscular dystrophy (DMD).
DMD is a rare genetic disease that progressively weakens the muscles and currently has no cure. Sarepta’s Elevidys promised a ray of hope for DMD patients, but the recent developments have cast serious doubts over the drug’s safety profile. The fatalities, attributed to acute liver failure, have raised questions about the adequacy of the warnings provided by the company regarding the drug’s potential risks.
Stock Price Impact: A Significant Downfall
The disclosure of the first fatality on March 18, 2025, led to a sharp plunge in Sarepta’s stock price. The share price nosedived by $27.81 or 27.44%, closing at $73.54. This crash underscored the investors’ concerns about the impact of the incident on Sarepta’s financial future.
Sadly, the situation further deteriorated on June 16, 2025, when Sarepta reported a second fatality. In response to this unfortunate incident, the company suspended its clinical trial and halted Elevidys distribution for non-ambulatory patients. This announcement triggered another significant stock price drop, this time of $15.24 per share or 42.12%, which brought the closing price down to $20.94.
The cumulative share price drop following the two incidents significantly eroded the market capitalization of Sarepta and highlighted the level of investor apprehension surrounding the company’s prospects.
Analyst Ratings and Market Response: A Mixed Bag
Following the second incident’s announcement, Cowen & Co. downgraded Sarepta from a “Buy” to a “Hold” rating on June 18, 2025, when the stock was priced at $20.77. This is a significant shift in the investment firm’s stance, reflecting growing uncertainties about Sarepta’s future.
On the other hand, Wells Fargo maintained its “Overweight” rating on Sarepta’s stock. However, it adjusted the price target downwards from $100 to $75, acknowledging the ongoing uncertainties. The revised price target reflects a significant discount to the previous target, suggesting that the investment bank is factoring in potential risks.
Current Stock Performance: The Struggle Continues
As of now, Sarepta’s stock is trading at $19.25 per share, marking a 4.13% decrease with a $0.83 change. The stock today has fluctuated between $18.70 and $19.76, far below its 52-week high of $168.31. The 52-week low stands at $18.30, suggesting that the stock is nearing its lowest level in the past year.
This recent performance paints a gloomy picture for Sarepta, which has a market capitalization of approximately $1.89 billion. Trading volume stands at 4,203,125 shares on the NASDAQ, indicating that the stock remains actively traded despite the ongoing uncertainty.
In conclusion, Sarepta Therapeutics is currently under significant pressure due to the investigation by Pomerantz LLP and the potential impact on its key drug, Elevidys. The company’s future now hinges on the outcomes of this investigation and its ability to reassure investors and regain their trust.